Abstract
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of blastocyst stage embryos, while induced pluripotent stem (iPS) cells are generated from somatic cells through transient overexpression of defined transcription factors. When transplanted into a preimplantation embryo, ES cells and iPS cells can differentiate into any cell type, including germ cells. Moreover, they can grow in culture indefinitely while maintaining pluripotency. In vitro differentiation of ES cells and iPS cells recapitulates many aspects of in vivo embryogenesis. The acquisition of neural fates (neural induction) in ES cells can be controlled by bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and Wnt signaling, while the production of specific neural cell types (neural patterning) can be controlled by exogenous patterning signals such as Wnt, BMP, Shh, FGF, and retinoic acid. In response to these signals, ES cells can differentiate into a wide range of neural cell types that correlate with their positions along the anterior-posterior and dorsal-ventral axes. ES cell and iPS cell culture systems will provide materials for cell replacement therapy, and can be used as in vitro models for disease and drug testing as well as development. Here we review spatiotemporal control of neural differentiation of mammalian pluripotent stem cells, with a special emphasis on the relationship between in vivo embryogenesis and in vitro ES cell differentiation. Retinal differentiation from ES cells and iPS cells is also outlined.
Keywords: Cell fate, embryonic stem (ES) cell, default model, induced pluripotent stem (iPS) cell, neurogenesis, photoreceptor, regeneration, retina, bone morphogenetic protein, fibroblast growth factor, retinal pigment epithelium, xenopus laevis, stromal cell-derived inducing activity, embryogenesis
CNS & Neurological Disorders - Drug Targets
Title: Neural Induction and Patterning in Mammalian Pluripotent Stem Cells
Volume: 10 Issue: 4
Author(s): Fumitaka Osakada and Masayo Takahashi
Affiliation:
Keywords: Cell fate, embryonic stem (ES) cell, default model, induced pluripotent stem (iPS) cell, neurogenesis, photoreceptor, regeneration, retina, bone morphogenetic protein, fibroblast growth factor, retinal pigment epithelium, xenopus laevis, stromal cell-derived inducing activity, embryogenesis
Abstract: Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of blastocyst stage embryos, while induced pluripotent stem (iPS) cells are generated from somatic cells through transient overexpression of defined transcription factors. When transplanted into a preimplantation embryo, ES cells and iPS cells can differentiate into any cell type, including germ cells. Moreover, they can grow in culture indefinitely while maintaining pluripotency. In vitro differentiation of ES cells and iPS cells recapitulates many aspects of in vivo embryogenesis. The acquisition of neural fates (neural induction) in ES cells can be controlled by bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and Wnt signaling, while the production of specific neural cell types (neural patterning) can be controlled by exogenous patterning signals such as Wnt, BMP, Shh, FGF, and retinoic acid. In response to these signals, ES cells can differentiate into a wide range of neural cell types that correlate with their positions along the anterior-posterior and dorsal-ventral axes. ES cell and iPS cell culture systems will provide materials for cell replacement therapy, and can be used as in vitro models for disease and drug testing as well as development. Here we review spatiotemporal control of neural differentiation of mammalian pluripotent stem cells, with a special emphasis on the relationship between in vivo embryogenesis and in vitro ES cell differentiation. Retinal differentiation from ES cells and iPS cells is also outlined.
Export Options
About this article
Cite this article as:
Osakada Fumitaka and Takahashi Masayo, Neural Induction and Patterning in Mammalian Pluripotent Stem Cells, CNS & Neurological Disorders - Drug Targets 2011; 10 (4) . https://dx.doi.org/10.2174/187152711795563958
DOI https://dx.doi.org/10.2174/187152711795563958 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arterial Dilatation-Related Diseases: The Prerequisite Condition of Arterial Elastic Tissue Damage and Endovascular Treatment
Recent Patents on Medical Imaging Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design
Current Medicinal Chemistry Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics The use of Human Allogenic Graft (HBA) for Maxillary Bone Regeneration: Review of Literature and Case Reports
Current Pharmaceutical Design Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Current Neurovascular Research Female Infertility and Antioxidants
Current Women`s Health Reviews Pharmacological Effects of Biotin in Animals
Mini-Reviews in Medicinal Chemistry Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Inflammation, Infection and Preterm Birth
Current Pharmaceutical Design Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design